Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Leads Biolabs' Opamtistomig NDA Accepted in China for Advanced EP-NEC

23 August 2026 · By · Wire by Fusion42

Published

23 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biopharmaapac.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Leads Biolabs’ Opamtistomig, a PD-L1/4-1BB bispecific antibody for advanced extrapulmonary neuroendocrine carcinoma, has had its NDA accepted by China's NMPA with Priority Review status.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a rare chance to lead in 4-1BB immunotherapy as Leads Biolabs nears first global approval in China. Act now to engage China-facing oncology partners or rethink trial design for this new target regionally.

◆ Coverage

1 source · 23 Aug 2026

◆ Related on Wire

◆ Topics

Biotechimmunotherapyoncology4-1bbclinical-trialsdrug-approval